Biotechnology

Krystal Biotech

Krystal Biotech released FY2026 Q1 earnings on May 4 Pre-Market EST, actual revenue USD 116.36 M (forecast USD 112.13 M), actual EPS USD 1.83 (forecast USD 1.4375)

Krystal Biotech to release FY2026 Q1 earnings on May 4 Pre-Market EST, forecast revenue USD 112.18 M, EPS USD 1.4237

Krish S. Krishnan Sells Krystal Biotech Ordinary Shares

Krystal Biotech released FY2025 annual earnings on February 17 Pre-Market (EST), actual revenue USD 389.13 M (forecast USD 387.6 M), actual EPS USD 6.84 (forecast USD 6.8211)

Krystal Biotech released FY2025 Q4 earnings on February 17 Pre-Market (EST), actual revenue USD 107.11 M (forecast USD 105.13 M), actual EPS USD 1.7039 (forecast USD 1.4085)

Krystal Biotech Inc.'s Chief Accounting Officer Disposed of Common Stock

Krystal Biotech to Release FY2025 Q4 Earnings on February 17, 2026, Pre-Market EST; Forecast Revenue USD 105.3 M, EPS USD 1.4337

Krystal Biotech Inc's Drug KB707 Receives FDA RMAT Designation

Krystal Biotech Inc. Outlines 2026 Financial Outlook

TD Cowen Raises Krystal Biotech's Target Price to $306 and Maintains 'Buy' Rating

Analyst Maintains Buy Rating for Krystal Biotech

Krystal Biotech to Announce Mid-Term Clinical Update for KB407 Study

Krish S Krishnan sold 50,000 shares of Krystal Biotech stock

Chardan Capital Raises Krystal Biotech Target Price, Stock Rises

Sami Corwin Recommends Buy Rating for Krystal Biotech

Pantginis Reiterates Strong Buy Rating For Krystal Biotech

Krystal Biotech released FY2025 9 Months Earnings on November 3 Pre-Market (EST), actual revenue USD 282.03 M, actual EPS USD 5.15

Krystal Biotech released FY2025 Q3 earnings on November 3 Pre-Market (EST), actual revenue USD 97.8 M (forecast USD 93.42 M), actual EPS USD 2.66 (forecast USD 1.0862)

Krystal Biotech Reports Significant Q3 2025 Net Revenue Growth

Krystal Biotech to Release FY2025 Q3 Earnings on November 3, Pre-Market EST, Forecast Revenue USD 93.42 M, EPS USD 1.0862

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

KRYS

Krystal Biotech's beremagene geperpavec has received approval from the UK's Medicines and Healthcare products Regulatory Agency for treating wounds in patients with dystrophic epidermolysis bullosa from birth. The gel showed a 67% complete healing rate in a study of 31 patients over six months. The stock price is currently at $308.93, down 2.33%.

Fidelity

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

IBBQ

LABU

ARKG

SBIO

Krystal Biotech (NASDAQ:KRYS) reached a new 52-week high of $314.00, closing at $310.63 with a trading volume of 23,480 shares. Analysts have upgraded the stock, with Weiss Ratings moving it from "hold" to "buy" and Bank of America raising its price target from $288 to $318. The company reported a quarterly EPS of $1.83, exceeding estimates, and has a market cap of $9.20 billion. Insider trading activity includes significant sales by executives, while institutional ownership stands at 86.29%.

Market Beat

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Bank of America

Jefferies Financial

ROYAL BANK OF CANADA

Bank of Montreal

Canadian Imperial Bank Comm

Annaly Capital Mgmt

Sculptor Capital

Arqit Quantum

Nano Labs

Mirrabooka Investments Ltd

Power Assets Holdings

Costa Group Holdings Ltd. TEMP

Impact Shares YWCA Women Empowerment

Nomura Holdings, Inc.

LG QRAFT AI-Powered US Large Cap Core ETF

Japan Investment Adviser Co., Ltd.

Cetus Capital Acquisition Corp.

Russell Investment Management LLC

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Arqit Quantum - CW26

POWER ASSETS

Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week High  - Here's Why

HC Wainwright has raised its FY2026 earnings estimate for Krystal Biotech (NASDAQ:KRYS) from $5.78 to $6.83 per share, maintaining a "Buy" rating and a target price of $310. The consensus estimate for the company's current full-year earnings is $7.58 per share. Krystal Biotech reported $1.83 EPS for the latest quarter, exceeding expectations. Analysts have generally rated the stock as a "Moderate Buy" with an average target price of $324.11. Recent insider sales and institutional investments have also been noted.

iShares US Pharma

HC Wainwright Expects Increased Earnings for Krystal Biotech

Krystal Biotech (KRYS) reported strong Q1 earnings, with earnings of $1.83 per share and sales of $116.357 million, both exceeding analyst estimates. Despite a 1% drop in shares to $284.01, analysts have raised their price targets, with Evercore ISI maintaining an Outperform rating and increasing the target from $295 to $300, while Citigroup raised its Buy target from $371 to $378. CEO Krish S. Krishnan highlighted the company's momentum and potential for future growth with ongoing global expansion and pipeline developments.

benzinga_article

iShares Global Healthcare

Health Care Select Sector SPDR

VG Health

Evercore

Citigroup

NASDAQ Composite Index

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech's Q1 earnings call highlighted strong revenue growth, with net revenue for VYJUVEK reaching $116.4 million, a 32% year-over-year increase. The company reported its 11th consecutive quarter of positive EPS, with net income rising to $55.9 million. Gross margin improved to 95%, and cash reserves exceeded $1 billion. International sales contributed significantly, with plans for expansion in Europe and Japan. However, management noted challenges such as insurance churn and rising operational costs. The company remains focused on disciplined spending and anticipates multiple clinical readouts in the coming year.

Tip Ranks

Krystal Biotech Earnings Call Highlights Profitable Growth

Chardan Capital has maintained a Buy rating on Krystal Biotech (KRYS) with a price target of $323. Analyst Geulah Livshits, a 5-star analyst, has an average return of 12.7% and a 37.88% success rate. The overall analyst consensus for Krystal Biotech is a Strong Buy, with an average price target of $325.13.

Palvella Therapeutics

Iovance Biotherapeautics

Rocket Pharma

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 EPS, exceeding expectations by $0.38. The company generated revenue of $116.36 million, surpassing the consensus estimate of $112.11 million. With a net margin of 52.64% and a return on equity of 18.69%, Krystal Biotech's stock performance remains strong, with a market cap of $7.83 billion. Recent insider sales and institutional investments indicate active trading, while analysts maintain a positive outlook with multiple buy ratings and a consensus price target of $326.25.

Danske Bank

UMB Financial

Goldman Sachs

GS Hldg R

Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

NCLH

FANG

SOXL

SOXX

Today, major companies including ON Semiconductor, Transocean, and Vertex Pharmaceuticals are set to report earnings. Investors are closely monitoring options activity for insights into potential stock movements post-announcement. Expected earnings moves based on options prices are as follows: NCLH: +/- 9.41% (before market open), ON: +/- 11.16%, RIG: +/- 8.77%, VRTX: +/- 5.61%, FANG: +/- 6.74%, IIPR: +/- 8.53%, PINS: +/- 14.39%, PLTR: +/- 9.82%, GRAB: +/- 9.26% (after market close). Options trading carries risks; thorough research is advised.

Krystal Biotech(KRYS.US)